Abstract
During studies of pharmacokinetics of IVIG in neonates, an infant with a serious lower respiratory tract infection was treated with IVIG and experienced an unexpectedly prompt recovery. Viral cultures of the infant's secretions subsequently grew RSV. Analysis of the IVIG lot infused yielded an RSV neutralizing titer of 1:3,276. This prompted a screen of 23 other lots of human IVIG prepared by 3 manufacturers (Cutter Inc., 7 lots; Sandoz Inc., 9 lots; Hyland Laboratories, 7 lots). Eight lots had neutralizing RSV titers exceeding 1:10,240; titers of the others ranged from 1:1,559 to 1:9,344 (ave. 1:4,438). RSV complement fixation (CF) titers generally mirrored the neutralizing titers. However, the RSV CF titers in the 20 lots were generally about 10-fold higher than CF titers to influenza A, B, parainfluenza 1, 2, 3 and adenoviruses. Reinfection of humans by RSV is common. Coupled with the annual RSV outbreaks in most communities, recurrent reexposure probably accounts for the high titers in the IVIG lots. The data suggested that IVIG may be suitable for prophylaxis or treatment of RSV infections. Utilization of high titered RSV-IVIG preparations for passive immunotherapy of RSV disease is currently being examined in cotton rat and owl monkey models.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hemming, V., Weisman, L., Prince, G. et al. RESPIRATORY SYNCYTIAL VIRUS (RSV) NEUTRALIZING ANTIBODY TITERS HUMAN IMMUNE SERUM GLOBULIN FOR INTRAVENOUS (IVIG) INFUSION. Pediatr Res 18 (Suppl 4), 277 (1984). https://doi.org/10.1203/00006450-198404001-01105
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-01105